Search

Introduction: While breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that comorbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/comorbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor-positive disease and rates of chemotherapy for high-risk disease. Methods and analysis: This multicentre, parallel group, pragmatic cluster randomised controlled trial (RCT) (2015-18) reported here is nested within a larger ongoing ‘Age Gap Cohort Study’ (2012-18RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions to assist in the treatment decision making for early breast cancer in older women. The interventions include two patient decision aids (primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy) and a clinical treatment outcomes algorithm for clinicians. Ethics and dissemination: National and local ethics committee approval was obtained for all UK participating sites. Results from the trial will be submitted for publication in international peer-reviewed scientific journals.

With business analytics is becoming increasingly strategic to all types of organizations and with many companies struggling to create a meaningful impact with this emerging technology, this work—based on the combined experience of 10 organizations that display excellence and expertise on the subject—shares the best practices, discusses the management aspects and sociology that drives success, and uncovers the five key aspects behind the success of some of the top business analytics programs in the industry. Readers will learn about numerous topics, including how to create and manage a changing business analytics strategy; align business priorities to technological innovation; quantify and demonstrate tangible business value; implement program processes that balance agility, empowerment, and control; and architecting a business analytics technology solution with future innovation in mind. This is the ideal resource for any organization that wants to learn how a business analytics program can help manage value, employees, and technology to translate strategies into actionable insight and achievement.

With business analytics is becoming increasingly strategic to all types of organizations and with many companies struggling to create a meaningful impact with this emerging technology, this work—based on the combined experience of 10 organizations that display excellence and expertise on the subject—shares the best practices, discusses the management aspects and sociology that drives success, and uncovers the five key aspects behind the success of some of the top business analytics programs in the industry. Readers will learn about numerous topics, including how to create and manage a changing business analytics strategy; align business priorities to technological innovation; quantify and demonstrate tangible business value; implement program processes that balance agility, empowerment, and control; and architecting a business analytics technology solution with future innovation in mind. This is the ideal resource for any organization that wants to learn how a business analytics program can help manage value, employees, and technology to translate strategies into actionable insight and achievement.

With business analytics is becoming increasingly strategic to all types of organizations and with many companies struggling to create a meaningful impact with this emerging technology, this work—based on the combined experience of 10 organizations that display excellence and expertise on the subject—shares the best practices, discusses the management aspects and sociology that drives success, and uncovers the five key aspects behind the success of some of the top business analytics programs in the industry. Readers will learn about numerous topics, including how to create and manage a changing business analytics strategy; align business priorities to technological innovation; quantify and demonstrate tangible business value; implement program processes that balance agility, empowerment, and control; and architecting a business analytics technology solution with future innovation in mind. This is the ideal resource for any organization that wants to learn how a business analytics program can help manage value, employees, and technology to translate strategies into actionable insight and achievement.

With business analytics is becoming increasingly strategic to all types of organizations and with many companies struggling to create a meaningful impact with this emerging technology, this work—based on the combined experience of 10 organizations that display excellence and expertise on the subject—shares the best practices, discusses the management aspects and sociology that drives success, and uncovers the five key aspects behind the success of some of the top business analytics programs in the industry. Readers will learn about numerous topics, including how to create and manage a changing business analytics strategy; align business priorities to technological innovation; quantify and demonstrate tangible business value; implement program processes that balance agility, empowerment, and control; and architecting a business analytics technology solution with future innovation in mind. This is the ideal resource for any organization that wants to learn how a business analytics program can help manage value, employees, and technology to translate strategies into actionable insight and achievement.

Introduction: While breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that comorbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/comorbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor-positive disease and rates of chemotherapy for high-risk disease. Methods and analysis: This multicentre, parallel group, pragmatic cluster randomised controlled trial (RCT) (2015-18) reported here is nested within a larger ongoing ‘Age Gap Cohort Study’ (2012-18RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions to assist in the treatment decision making for early breast cancer in older women. The interventions include two patient decision aids (primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy) and a clinical treatment outcomes algorithm for clinicians. Ethics and dissemination: National and local ethics committee approval was obtained for all UK participating sites. Results from the trial will be submitted for publication in international peer-reviewed scientific journals.

Introduction: While breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that comorbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/comorbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor-positive disease and rates of chemotherapy for high-risk disease. Methods and analysis: This multicentre, parallel group, pragmatic cluster randomised controlled trial (RCT) (2015-18) reported here is nested within a larger ongoing ‘Age Gap Cohort Study’ (2012-18RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions to assist in the treatment decision making for early breast cancer in older women. The interventions include two patient decision aids (primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy) and a clinical treatment outcomes algorithm for clinicians. Ethics and dissemination: National and local ethics committee approval was obtained for all UK participating sites. Results from the trial will be submitted for publication in international peer-reviewed scientific journals.

Introduction: While breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that comorbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/comorbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor-positive disease and rates of chemotherapy for high-risk disease. Methods and analysis: This multicentre, parallel group, pragmatic cluster randomised controlled trial (RCT) (2015-18) reported here is nested within a larger ongoing ‘Age Gap Cohort Study’ (2012-18RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions to assist in the treatment decision making for early breast cancer in older women. The interventions include two patient decision aids (primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy) and a clinical treatment outcomes algorithm for clinicians. Ethics and dissemination: National and local ethics committee approval was obtained for all UK participating sites. Results from the trial will be submitted for publication in international peer-reviewed scientific journals.